• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Characteristics of Central Retinal Vein Occlusion in African Americans.非裔美国人中心性视网膜静脉阻塞的特征
J Vitreoretin Dis. 2019 Nov 6;4(3):186-191. doi: 10.1177/2474126419882829. eCollection 2020 Jun.
2
Baseline Characteristics and Outcomes After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema in Participants With Hemiretinal Vein Occlusion Compared With Participants With Central Retinal Vein Occlusion: Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2) Report 18.与中央视网膜静脉阻塞患者相比,视网膜静脉阻塞 2 期(SCORE2)研究报告 18 中接受抗血管内皮生长因子治疗的半视网膜静脉阻塞患者的基线特征和结局
JAMA Ophthalmol. 2022 May 1;140(5):458-464. doi: 10.1001/jamaophthalmol.2022.0352.
3
Efficacy and safety of dexamethasone intravitreal implant in patients with retinal vein occlusion resistant to anti-VEGF therapy: a 12-month prospective study.玻璃体内注射地塞米松植入物治疗抗VEGF治疗耐药的视网膜静脉阻塞患者的疗效和安全性:一项为期12个月的前瞻性研究。
Cutan Ocul Toxicol. 2019 Dec;38(4):330-337. doi: 10.1080/15569527.2019.1614020. Epub 2019 May 27.
4
Treatment Patterns and Clinical Outcomes for Central Retinal Vein Occlusion in the Antivascular Endothelial Growth Factor Era.抗血管内皮生长因子时代视网膜中央静脉阻塞的治疗模式与临床结局
J Vitreoretin Dis. 2019 Oct 14;4(1):13-21. doi: 10.1177/2474126419878922. eCollection 2020 Jan-Feb.
5
[Anti-VEGF therapy in the treatment of anterior segment neovascularization secondary to central retinal vein occlusion].[抗血管内皮生长因子疗法治疗视网膜中央静脉阻塞继发的眼前段新生血管形成]
J Fr Ophtalmol. 2015 May;38(5):414-20. doi: 10.1016/j.jfo.2014.11.007. Epub 2015 May 5.
6
Outcomes in Retinal Vein Occlusions Presenting with Poor Visual Acuity Treated with Anti-Vascular Endothelial Growth Factor Therapy: Prognosis and Predictive Factors.抗血管内皮生长因子疗法治疗视力低下的视网膜静脉阻塞的预后及预测因素
Ophthalmol Retina. 2021 Sep;5(9):888-900. doi: 10.1016/j.oret.2020.11.010. Epub 2020 Nov 20.
7
Longer-Term Anti-VEGF Therapy Outcomes in Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Vein Occlusion-Related Macular Edema: Clinical Outcomes in 130 247 Eyes.新生血管性年龄相关性黄斑变性、糖尿病性黄斑水肿和静脉阻塞相关性黄斑水肿的长期抗 VEGF 治疗结果:130247 只眼的临床结果。
Ophthalmol Retina. 2022 Sep;6(9):796-806. doi: 10.1016/j.oret.2022.03.021. Epub 2022 Apr 2.
8
Photocoagulation for retinal vein occlusion.视网膜静脉阻塞的光凝治疗
Prog Retin Eye Res. 2021 Nov;85:100964. doi: 10.1016/j.preteyeres.2021.100964. Epub 2021 Mar 11.
9
Short-term results of endovascular surgery with tissue plasminogen activator injection for central retinal vein occlusion.组织纤溶酶原激活剂注射血管内手术治疗视网膜中央静脉阻塞的短期结果
Graefes Arch Clin Exp Ophthalmol. 2017 Nov;255(11):2135-2140. doi: 10.1007/s00417-017-3763-1. Epub 2017 Aug 12.
10
Long-term effect of early intervention with single intravitreal injection of bevacizumab followed by panretinal and macular grid photocoagulation in central retinal vein occlusion (CRVO) with macular edema: a pilot study.长期疗效观察:玻璃体内单次注射贝伐单抗联合视网膜全光凝及黄斑格栅样光凝治疗视网膜中央静脉阻塞伴黄斑水肿的疗效:一项初步研究。
Eye (Lond). 2011 Feb;25(2):239-44. doi: 10.1038/eye.2010.225.

引用本文的文献

1
Adverse effects of CXCR2 deficiency in mice reared under non-gnotobiotic conditions.非无菌条件下饲养的 CXCR2 缺陷小鼠的不良反应。
Sci Rep. 2024 Oct 30;14(1):26159. doi: 10.1038/s41598-024-75532-9.
2
Prevalence and systemic associations of retinal vascular occlusions in Sub-Saharan Africa.撒哈拉以南非洲视网膜血管闭塞的患病率及系统相关性。
Ann Afr Med. 2023 Jul-Sep;22(3):279-285. doi: 10.4103/aam.aam_44_22.
3
Racial differences in quantitative optical coherence tomography angiography findings between older non-diabetics with co-morbidities.老年人合并症中非糖尿病患者定量光学相干断层扫描血管造影结果的种族差异。
PLoS One. 2023 May 5;18(5):e0285360. doi: 10.1371/journal.pone.0285360. eCollection 2023.
4
Central Retinal Vein Occlusion: The Effect of Antiplatelet and Anticoagulant Agents.视网膜中央静脉阻塞:抗血小板和抗凝药物的作用
J Vitreoretin Dis. 2021 Jul 30;6(2):97-103. doi: 10.1177/24741264211028508. eCollection 2022 Mar-Apr.
5
Evaluation of flow of chorioretinal capillaries in healthy black and white subjects using optical coherence tomography angiography.应用光学相干断层扫描血管造影评估健康黑白人种的脉络膜毛细血管血流。
Sci Rep. 2021 Nov 8;11(1):21886. doi: 10.1038/s41598-021-01380-6.

本文引用的文献

1
USE OF THE ISCHEMIC INDEX ON WIDEFIELD FLUORESCEIN ANGIOGRAPHY TO CHARACTERIZE A CENTRAL RETINAL VEIN OCCLUSION AS ISCHEMIC OR NONISCHEMIC.应用广角荧光素血管造影的缺血指数对中央性视网膜静脉阻塞进行缺血或非缺血特征描述。
Retina. 2019 Jun;39(6):1033-1038. doi: 10.1097/IAE.0000000000002126.
2
Displacement of the Lamina Cribrosa in Response to Acute Intraocular Pressure Elevation in Normal Individuals of African and European Descent.非洲和欧洲裔正常个体中筛板在急性眼压升高时的移位
Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3331-9. doi: 10.1167/iovs.15-17940.
3
Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.玻璃体内注射阿柏西普治疗视网膜中央静脉阻塞继发黄斑水肿:3期GALILEO研究的18个月结果
Am J Ophthalmol. 2014 Nov;158(5):1032-8. doi: 10.1016/j.ajo.2014.07.027. Epub 2014 Jul 25.
4
The 10-year incidence and risk factors of retinal vein occlusion: the Beijing eye study.视网膜静脉阻塞的 10 年发生率及相关因素:北京眼病研究。
Ophthalmology. 2013 Apr;120(4):803-8. doi: 10.1016/j.ophtha.2012.09.033. Epub 2013 Jan 23.
5
A longitudinal analysis of risk factors associated with central retinal vein occlusion.与中央视网膜静脉阻塞相关的危险因素的纵向分析。
Ophthalmology. 2013 Feb;120(2):362-70. doi: 10.1016/j.ophtha.2012.07.080. Epub 2012 Nov 20.
6
Prevalence and associations of retinal vein occlusions: the Central India Eye and Medical Study.视网膜静脉阻塞的患病率及相关因素:中央印度眼与医学研究。
Retina. 2013 Jan;33(1):152-9. doi: 10.1097/IAE.0b013e318260246f.
7
Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.雷珠单抗治疗视网膜静脉阻塞所致黄斑水肿的长期随访:HORIZON 试验。
Ophthalmology. 2012 Apr;119(4):802-9. doi: 10.1016/j.ophtha.2011.12.005. Epub 2012 Feb 1.
8
Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results.地塞米松玻璃体内植入物治疗与分支或中央视网膜静脉阻塞相关的黄斑水肿患者的 12 个月研究结果。
Ophthalmology. 2011 Dec;118(12):2453-60. doi: 10.1016/j.ophtha.2011.05.014. Epub 2011 Jul 20.
9
African Descent and Glaucoma Evaluation Study (ADAGES): II. Ancestry differences in optic disc, retinal nerve fiber layer, and macular structure in healthy subjects.非洲裔与青光眼评估研究(ADAGES):II. 健康受试者视盘、视网膜神经纤维层和黄斑结构的种族差异。
Arch Ophthalmol. 2010 May;128(5):541-50. doi: 10.1001/archophthalmol.2010.49.
10
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.随机、假手术对照试验研究地塞米松眼内植入剂治疗视网膜静脉阻塞所致黄斑水肿患者。
Ophthalmology. 2010 Jun;117(6):1134-1146.e3. doi: 10.1016/j.ophtha.2010.03.032. Epub 2010 Apr 24.

非裔美国人中心性视网膜静脉阻塞的特征

Characteristics of Central Retinal Vein Occlusion in African Americans.

作者信息

Kiew Sieh Yean, Thomas George N, Thomas Akshay S, Fekrat Sharon

机构信息

Singapore National Eye Centre, Singapore.

Department of Ophthalmology, National University Hospital, Singapore.

出版信息

J Vitreoretin Dis. 2019 Nov 6;4(3):186-191. doi: 10.1177/2474126419882829. eCollection 2020 Jun.

DOI:10.1177/2474126419882829
PMID:37007449
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9982256/
Abstract

PURPOSE

This article studies whether the characteristics and clinical course of African American patients with central retinal vein occlusion (CRVO) differ from other racial groups.

METHODS

This retrospective cohort study included consecutive patients diagnosed with CRVO at Duke Eye Center, Durham, North Carolina. Presenting characteristics, examination findings, treatment course, and functional and structural outcomes were compared based on patient-reported race.

RESULTS

A total of 479 patients with CRVO were included (64.7% white, 22.2% African American, 1.7% mixed race, and 11.4% other races). African American patients were older (68.1 vs 64.3 years, = .049), more likely to be hypertensive ( = .001) and diabetic ( = .000), and had higher rates of open-angle glaucoma ( < .000). Presenting visual acuity (VA) was worse in African Americans (logarithm of the minimum angle of resolution 1.25 vs 0.96, = .010). There were no significant differences in the proportion of patients requiring panretinal photocoagulation, intravitreal antivascular endothelial growth factor (anti-VEGF), or intravitreal corticosteroid; however, analysis of treatment-naive individuals showed a higher number of anti-VEGF injections in the first year in African Americans. Final VA was not significantly different between groups, but African Americans had higher rates of neovascular sequelae (25.0% vs 11.8%, = .019; odds ratio, 2.295, = .088).

CONCLUSIONS

African Americans with CRVO presented with more severe visual impairment and more systemic and ocular risk factors for CRVO. Treatment-naive African Americans had a greater treatment burden during the first year of follow-up.

摘要

目的

本文研究非裔美国中心性视网膜静脉阻塞(CRVO)患者的特征和临床病程是否与其他种族群体不同。

方法

这项回顾性队列研究纳入了北卡罗来纳州达勒姆市杜克眼科中心连续诊断为CRVO的患者。根据患者报告的种族比较了呈现特征、检查结果、治疗过程以及功能和结构结果。

结果

共纳入479例CRVO患者(64.7%为白人,22.2%为非裔美国人,1.7%为混血,11.4%为其他种族)。非裔美国患者年龄更大(68.1岁对64.3岁,P = 0.049),更易患高血压(P = 0.001)和糖尿病(P = 0.000),开角型青光眼发病率更高(P < 0.000)。非裔美国人的初始视力(VA)更差(最小分辨角对数1.25对0.96,P = 0.010)。在需要全视网膜光凝、玻璃体内抗血管内皮生长因子(抗VEGF)或玻璃体内皮质类固醇治疗的患者比例方面无显著差异;然而,对未接受过治疗的个体分析显示,非裔美国人在第一年接受抗VEGF注射的次数更多。两组的最终视力无显著差异,但非裔美国人新生血管后遗症发生率更高(25.0%对11.8%,P = 0.019;优势比,2.295,P = 0.088)。

结论

患有CRVO的非裔美国人存在更严重的视力损害以及更多的CRVO全身和眼部危险因素。未接受过治疗的非裔美国人在随访的第一年治疗负担更大。